Treatment of Post-bariatric Hypoglycaemia

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

May 15, 2022

Study Completion Date

December 15, 2022

Conditions
Hyperinsulinemic HypoglycemiaPostprandial Hypoglycemia
Interventions
DRUG

Dasiglucagon

Abdominal s.c. self-administration 120 µg of dasiglucagon when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.

DEVICE

HyoPen

multi-dose reusable pen injector

DRUG

Placebo

Abdominal s.c. self-administration with placebo when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.

Trial Locations (1)

2900

Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, Hellerup

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Zealand Pharma

INDUSTRY

lead

Filip Krag Knop

OTHER